Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Recombinant Norovirus Bivalent Vaccine in Healthy Subjects
NCT04941261Phase 2Unknown
- Sponsor
- Serum Institute of India
- Start
- Jun 2021
- Primary completion
- Feb 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant norovirus bivalent (GI.1/GII.4) vaccine in norovirus infection, sponsored by Serum Institute of India. Status: unknown.
02
Drugs
recombinant norovirus bivalent (GI.1/GII.4) vaccine
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT04941261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941261.